MedTrace Logo

Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)

NCT03680183 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2018-09-28

No results posted yet for this study

Summary

The study will explore the characteristics in clinical pharmacokinetics of gefitinib, erlotinib,afatinib,osimertinib, crizotinib, apatinib, icotinib in Chinese patients of Non-small-cell lung cancer and hepatitis B. The study is self-controlled. The plasma concentration of tyrosine kinase inhibitors will be analyzed before and after system treatment of HBV.

Conditions

Interventions

DRUG

Entecavir 1Mg Oral Tablet

The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)

Sponsors & Collaborators

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Shuzhong Cui, MD · Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2019-03-01
Completion
2021-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03680183 on ClinicalTrials.gov